Cetera Investment Advisers
PCVX icon

Cetera Investment Advisers’s Vaxcyte PCVX Stock Holding History

Cetera Investment Advisers’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$558K Buy
9,595
+1,798
+23% +$97.6K ﹤0.01% 3408
2025
Q4 		$360K Sell
7,797
-701
-8% -$31.4K ﹤0.01% 3728
2025
Q3 		$306K Buy
8,498
+817
+11% +$27.1K ﹤0.01% 3817
2025
Q2 		$250K Buy
7,681
+932
+14% +$30.6K ﹤0.01% 3553
2025
Q1 		$255K Buy
6,749
+1,665
+33% +$133K ﹤0.01% 3406
2024
Q4 		$416K Sell
5,084
-43
-0.8% -$4.27K ﹤0.01% 2826
2024
Q3 		$586K Buy
5,127
+399
+8% +$36K ﹤0.01% 2520
2024
Q2 		$357K Buy
4,728
+248
+6% +$16.9K ﹤0.01% 2877
2024
Q1 		$306K Buy
+4,480
New +$310K ﹤0.01% 3022

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Investment Advisers's PCVX Position: Q1 2026 in Review

Cetera Investment Advisers increased its Vaxcyte (PCVX) stake by 23% in Q1 2026, buying an estimated $97.6K and bringing the position to 9,595 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #3408.

Cetera Investment Advisers first reported a position in PCVX in Q1 2024 and has held it in 9 quarters since. The position peaked at $586K in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Cetera Investment Advisers held 9,595 shares of Vaxcyte worth $558K as of Q1 2026.
  • Cetera Investment Advisers bought 1,798 Vaxcyte shares in Q1 2026, an estimated $97.6K.
  • Vaxcyte made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #3408 holding.
  • Cetera Investment Advisers first reported a position in Vaxcyte in Q1 2024 and has held it in 9 quarters since.
  • Cetera Investment Advisers's Vaxcyte position peaked at $586K in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.